益气活血通络方干预对门静脉血栓形成大鼠门静脉再通的影响研究*

doi:10.3969/j.issn.1672-5069.2025.01.007

实用肝脏病杂志 ›› 2025, Vol. 28 ›› Issue (1): 24-27.doi: 10.3969/j.issn.1672-5069.2025.01.007

益气活血通络方干预对门静脉血栓形成大鼠门静脉再通的影响研究^*

田瑞渊, 魏超, 李勇

250000 济南市山东大学齐鲁医院高新区医院消化科(田瑞渊);济宁医学院中西医结合学院(魏超);山东中医药大学附属医院肝病科(李勇)

收稿日期:2024-08-12 出版日期:2025-01-10 发布日期:2025-02-07
通讯作者: 李勇,E-mail:liy1958@163.com
作者简介:田瑞渊,男,34岁,医学硕士,主治医师。E-mail:castiel9527@foxmail.com
基金资助:
^*山东省中西医结合专病防治基金资助项目(编号:YXH2019ZXY003)

Effect of Yiqi Huoxue Tongluo compound intervention on portal vein recanalization in rats with surgery-induced portal vein thrombosis

Tian Ruiyuan, Wei Chao, Li Yong

Department of Gastroenterology, Qilu Gaoxin Hospital, Affiliated to Shandong University, Jinan 250101, Shandong Province, China

Received:2024-08-12 Online:2025-01-10 Published:2025-02-07

摘要/Abstract

摘要： 目的探讨益气活血通络方对实验性大鼠门静脉血栓(PVT)再通的效果。方法将45只大鼠随机分为实验组40只和对照组5只,采取门静脉间断结扎联合钳夹法建立PVT模型,超声检查判断建模状态。将模型动物随机分为模型组6只、模型对照组6只、利伐沙班干预组12只和中药干预组12只。结果超声检查显示PVT模型制备成功;在药物干预2 w后,利伐沙班组再通率为44.4%(4/9),中药干预组为90.9%(10/11,P<0.05);病理学上,模型组、模型对照组、利伐沙班干预组门静脉表现为血管内膜损伤,中膜水肿增厚,大量胶原纤维附着,而中药干预组血管内膜基本完整,中膜略增厚,仅有少量的胶原纤维附着;中药干预组血清D-二聚体水平为(170.7±6.7)ng/mL,利伐沙班处理组为(176.8±7.3)ng/mL,显著低于模型组[(211.3±12.4)ng/mL,P<0.05]或模型对照组[(205.1±12.7)ng/mL,P<0.05]。结论采用间断结扎联合钳夹法成功建立稳定的大鼠PVT模型,益气活血通络方和利伐沙班均可处理使PVT再通,值得深入探讨。

关键词: 门静脉血栓, 间断结扎联合钳夹法, 利伐沙班, 益气活血通络方, 大鼠

Abstract: Objective This experiment aimed to investigate effect of Yiqi Huoxue Tongluo compound, herbal medicine, intervention on portal vein recanalization in rats with surgery-induced portal vein thrombosis (PVT). Method 45 rats were randomly divided into experimental (n=40) and control (n=5) group. The PVT model was established by intermittent portal vein ligation and clamping, and monitored by ultrasonography. Rats with PVT were randomly divided into model (n=6), model control (n=6), rivaroxaban-intervened (n=12) and herbal medicine-intervened (n=12) group. Result Ultrasonography showed PVT was successfully established; 2 weeks after intervention, the reperfusion rate in rivaroxaban group was 44.4% (4/9), and it was 90.9% (10/11, P<0.05) in herbal medicine-intervened group; pathologically, vascular intima injury, media edema and thickening, and collagenous fiber adhesion in model, model control and rivaroxaban group, while vascular intima basically intact with slightly thicken media and much less collagenous fiber adhesion in herbal medicine-intervened group; serum D-dimer levels in herbal and rivaroxaban-intervened groups were (170.7±6.7)ng/mL and (176.8±7.3)ng/mL, both significantly lower than [(211.3±12.4)ng/mL, P<0.05] in model or [(205.1±12.7)ng/mL, P<0.05] in model control group. Conclusion A stable rat PVT model is successfully established by using intermittent ligation and clamping. Both rivaroxaban and herbal medicine, Yiqi Huoxue Tongluo Formula are effective in promoting PVT recanalization, which needs further investigation.

Key words: Portal vein thrombosis, Intermittent ligation and clamping, Levaroxaban, Herbal medicine, Yiqi Huoxue Tongluo compound, Rats

田瑞渊, 魏超, 李勇. 益气活血通络方干预对门静脉血栓形成大鼠门静脉再通的影响研究^*[J]. 实用肝脏病杂志, 2025, 28(1): 24-27.

Tian Ruiyuan, Wei Chao, Li Yong. Effect of Yiqi Huoxue Tongluo compound intervention on portal vein recanalization in rats with surgery-induced portal vein thrombosis[J]. Journal of Practical Hepatology, 2025, 28(1): 24-27.

参考文献

[1] Koh JH, Liew ZH, Ng GK, et al. Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: A systematic review and meta-analysis. Dig Liver Dis,2022,54(1):56-62.
[2] Harding DJ,Perera MT,Chen F,et al. Portal vein thrombosis in cirrhosis:Controversies and latest developments. World J Gastroenterol,2015,21(22):6769-6784.
[3] Senzolo M, Garcia-Tsao G, García-Pagán JC. Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol, 2021,75(2):442-453.
[4] Leonardi F,Maria ND,Villa E. Anticoagulation in cirrhosis:a newparadigm. Clin Mol Hepatol,2017,23(1):13-21.
[5] Stine JG,Shah PM,Cornella SL,et al.Portal vein thrombosis,mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis .World J Hepatol,2015,7( 27) : 2774-2780.
[6] Qi XS,Su CP,Ren WR,et al.Association between portal vein thrombosis and risk of bleeding in liver cirrhosis: A systematic review of the literature. Clin Res Hepatol Gastroenterol,2015,39( 6):683-691.
[7] 车莹,黄晓铨,陈世耀.用循证观点看待肝硬化门静脉血栓诊治中的争议.肝脏,2022,27(3):261-264.
[8] Biolato M, Paratore M, Di Gialleonardo L, et al. Direct oral anticoagulant administration in cirrhotic patients with portal vein thrombosis: What is the evidence? World J Hepatol, 2022,14(4):682-695.
[9] 靳珂珂, 丁惠国. 肝硬化门静脉血栓形成风险监测及抗凝管理.实用肝脏病杂志,2024, 27(1): 3-6.
[10] Chun HS, Choe AR, Lee M, et al. Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis. Clin Mol Hepatol,2021,27(4):535-552.
[11] Fontana RJ. Prophylactic anticoagulation in cirrhotics: a paradox for prime time? Gastroenterology, 2012,143(5):1138-1141.
[12] 刘壮,陈纪宏,祁兴顺,等.门静脉血栓动物模型的建立和应用.临床肝胆病杂志,2024.40(1):29-32.
[13] Wang Z, Chen Z, Fan Z, et al. Traditional Chinese medicine on treating splenomegaly due to portal hypertension in cirrhosis: A protocol for systematic review and meta-analysis. Medicine (Baltimore), 2021,100(1):e24081.
[14] Zhang DQ, Mu YP, Xu Y, et al. Research progress in Chinese medicine preparations for promoting blood circulation and removing blood stasis for cirrhotic patients with portal vein thrombosis following splenectomy. Chin J Integr Med, 2022,28(9):855-863.
[15] Wei C, Qiu J, Wu Y,et al.Promising traditional Chinese medicine for the treatment of cholestatic liver disease process (cholestasis, hepatitis, liver fibrosis, liver cirrhosis). J Ethnopharmacol, 2022,297:115550.
[16] Guo Y, Dong S, Li M, et al. A new model of portal vein thrombosis in rats with cirrhosis induced by partial portal vein ligation plus carbon tetrachloride and intervened with rivaroxaban. BMC Gastroenterol, 2024,24(1):161.
[17] 张津瑜,陈文显,沈华,等.大鼠门静脉系统血栓形成模型的建立和观察.中国普通外科杂志,2018,27(6):724-731.
[18] 吴治念,肖滢,王亚东.肝硬化门静脉血栓形成机制和治疗新认识.中华肝脏病杂志,2022,30:(11):1280-1284.
[19] 张明.肝硬化门静脉血栓形成诊治新进展.实用肝脏病杂志, 2024, 27(1): 11-15.
[20] 中华医学会肝病学分会. 肝硬化诊治指南.实用肝脏病杂志,2019,22(6):770-792.
[21] Driever EG, von Meijenfeldt FA, Adelmeijer J, et al. Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus. Hepatology. 2022,75(4):898-911.
[22] Rodriguez-Castro K I , Vitale A , Fadin M,et al.A prediction model for successful lanticoagulation in cirrhotic portalvein thrombosis. Eur J Gastroenterol Hepatol,2019,31(1):34-42.

益气活血通络方干预对门静脉血栓形成大鼠门静脉再通的影响研究^*

Effect of Yiqi Huoxue Tongluo compound intervention on portal vein recanalization in rats with surgery-induced portal vein thrombosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	周云松, 赵琦, 胡芳, 李叙颖, 崔峻松, 黄敬, 黄娜娜, 赵一鹏. 葛根素通过抑制AHR/氧化应激途径改善酮康唑诱导的大鼠肝损伤研究[J]. 实用肝脏病杂志, 2024, 27(5): 669-672.
[2]	吴大海, 刘其林, 卢杰夫, 梁玉梅. 乙型肝炎肝硬化并发门静脉血栓形成患者中性粒细胞胞外陷阱标志物变化^*[J]. 实用肝脏病杂志, 2024, 27(3): 394-397.
[3]	靳珂珂, 丁惠国. 肝硬化门静脉血栓形成风险监测及抗凝管理^*[J]. 实用肝脏病杂志, 2024, 27(1): 3-6.
[4]	张明. 肝硬化门静脉血栓形成诊治新进展[J]. 实用肝脏病杂志, 2024, 27(1): 11-15.
[5]	石莹, 吕永燕, 杨增娣, 刘波, 娄方明, 徐军, 童清平. 超声剪切波弹性成像技术评估CCl₄诱导的肝损伤大鼠肝纤维化程度效能研究[J]. 实用肝脏病杂志, 2023, 26(4): 476-479.
[6]	史海涛, 鲁晓岚. 门静脉血栓及肝动脉-门静脉瘘诊治再认识^*[J]. 实用肝脏病杂志, 2023, 26(2): 160-163.
[7]	黄淡霞, 招志辉, 萧月兴, 何艳青. 小檗碱通过调节肠道菌群改善高脂饮食诱导的非酒精性脂肪性肝病大鼠肝组织炎症实验研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 23-26.
[8]	朱海艳, 范晓棠. 肝硬化并发门静脉血栓形成患者列线图预测模型分析及外部验证[J]. 实用肝脏病杂志, 2022, 25(6): 848-852.
[9]	曾婷, 雷向阳, 白晓苏. 氧化苦参碱对非酒精性脂肪性肝病大鼠肝脏保护作用研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 624-627.
[10]	李婷, 毛小荣, 张雪梅, 李俊峰. 脾切除术与TIPS术治疗肝硬化患者门静脉血栓发生率比较^*[J]. 实用肝脏病杂志, 2022, 25(5): 685-688.
[11]	汪晓燕, 钟雪玉, 吴春燕. 沙格列汀干预非酒精性脂肪性肝病合并2型糖尿病大鼠肝组织AMPK/mTOR-TFEB自噬信号通路蛋白表达变化^*[J]. 实用肝脏病杂志, 2022, 25(4): 476-479.
[12]	刘尚智, 张志强, 李昇锦. 丹栀逍遥散对D-氨基半乳糖/脂多糖诱导的大鼠急性肝损伤保护作用机制研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 179-182.
[13]	史雪丽, 张万里, 毛俊, 颜悦蓉. 自身免疫性肝炎大鼠血清IL-38和β2GPI水平及其与肝组织病变的关系^*[J]. 实用肝脏病杂志, 2021, 24(6): 803-806.
[14]	顾雪香, 李祥玉, 单勤星. 柴胡皂苷a通过影响PPARα信号通路对非酒精性脂肪性肝病大鼠肝脂肪变的保护作用^*[J]. 实用肝脏病杂志, 2021, 24(6): 807-810.
[15]	李伟之, 李培杰, 马富权, 刘梦莹, 薛挥. 应用利伐沙班抗凝治疗经皮血管内介入治疗的布加综合征患者疗效和安全性研究^*[J]. 实用肝脏病杂志, 2021, 24(5): 621-624.